Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kairos Pharma announced statistically significant Phase 2 interim efficacy results for ENV-105 plus apalutamide, showing a median PFS of 17.7 months compared to 2 months for apalutamide alone, with a P-value of 0.0008.
Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for metastatic prostate cancer, showing a statistically significant difference in progression-free survival.